Omaha, NE – Commitment to innovation is a core value at Streck. One example of that focus on innovation is using the newest research tools and techniques to develop real world applications for clinicians and molecular technologists. That’s exactly what Streck scientists have done in a study which demonstrates the adaptation of current PCR technology and chemistries to produce a simple-to-use exclusionary screening assay for myotonic dystrophy, a genetic disorder and the most common adult form of muscular dystrophy.

The paper, titled, “PCR amplification of a triple-repeat genetic target directly from whole blood in 15 minutes as a proof-of-principle PCR study for direct sample analysis for a clinically relevant target” by
Chris Connelly, PhD, Laura Porter and Joel TerMaat, PhD, is published in the December 2014 issue of BMC Medical Genetics (

The PCR assay described in this study amplified DM1 short tandem repeats in 15 minutes. The process amplified gene targets from whole blood samples and eliminated the need for the DNA extraction step prior to PCR. The outcome is a significant improvement in a clinical laboratory technologist’s time to results. The direct and rapid methodology used in this study could be applied to other conventional PCR-based genetic tests and sample matrices where genomic DNA is targeted for analysis within a given molecular diagnostic platform.

About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The company’s pursuit of innovative solutions has produced an extensive list of patented products. Streck’s core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit

What we offer

Upcoming Events >